Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.06 | $0 | -$91,250 |
| 2025 Q4 | 0.01 | $0 | -$125,178 |
| 2025 Q3 | 0.07 | $0 | $137,904 |
| 2025 Q2 | 0.07 | $0 | -$300,669 |
| 2025 Q1 | 130.51 | $0 | -$251,244 |
| 2024 Q4 | -0.03 | $0 | -$123 |
| 2024 Q3 |
| -0.01 |
| $0 |
| -$57,230 |
| 2024 Q2 | -0.01 | $0 | -$115 |